Neurocrine Biosciences (Neurocrine Biosciences) Total Stockholders Equity : $2,386 Mil (As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Neurocrine Biosciences Total Stockholders Equity?

Neurocrine Biosciences's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $2,386 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Neurocrine Biosciences's Book Value per Share for the quarter that ended in Mar. 2024 was $23.72. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Neurocrine Biosciences's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.21.

Neurocrine Biosciences Total Stockholders Equity Historical Data

The historical data trend for Neurocrine Biosciences's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences Total Stockholders Equity Chart

Neurocrine Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

636.90

1,126.20

1,374.00

1,707.80

2,232.00

Neurocrine Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															1,684.50	1,853.00	2,002.10	2,232.00	2,386.10

Neurocrine Biosciences (NAS:NBIX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Neurocrine Biosciences's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(2386.1	-	0)	/	100.58
	=	23.72

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Neurocrine Biosciences's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(259	+	252.9)	/	2386.1
	=	0.21

Neurocrine Biosciences Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurocrine Biosciences (Neurocrine Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (NAS:NBIX) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

NB3:Germany NB3:Germany N1BI34:Brazil

Address

12780 El Camino Real, San Diego, CA, USA, 92130

Website

https://www.neurocrine.com

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Executives

Kevin Charles Gorman	officer: Sr VP, Business Development	12790 EL CAMINO REAL, SAN DIEGO CA 92130
William H Rastetter	director	9885 TOWNE CENTRE DR., SAN DIEGO CA 92121
Kyle Gano	officer: Chief Business Dev Officer	NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Eiry Roberts	officer: Chief Medical Officer	C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEO CA 92130
Julie Cooke	officer: Chief Human Resources Officer	C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Gary A Lyons	director, officer: President and CEO	12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Darin Lippoldt	officer: Chief Legal Officer	C/O VOLCANO CORPORATION, 3661 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130
Jude Onyia	officer: Chief Scientific Officer	C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
David W. Boyer	officer: Chief Corp. Affairs Officer	C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Ingrid Delaet	officer: Chief Regulatory Officer	C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Matt Abernethy	officer: Chief Financial Officer	C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92121
Eric Benevich	officer: Chief Commerical Officer	C/O NEUROCRINE BIOSCIENCES, INC., 12790 EL CAMINO REAL, SAN DIEGO CA 92130
Christine A Poon	director	C/O JOHNSON & JOHNSON, ONE JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Malcolm Lloyd-smith	officer: Chief Regulatory Officer	12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Stephen A Sherwin	director	C/O CELL GENESYS, INC., 500 FORBES BLVD., SOUTH SAN FRANCISCO CA 94080